OBJECTIVES: Decreased concentrations of circulating soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) were recently reported to be associated with atherosclerosis, but there are still no data concerning its predictive performance. DESIGN AND METHODS: The current cross-sectional study investigates the potential of the novel atherosclerotic biomarker for the prediction of coronary artery disease (CAD). Serum sTWEAK was measured by ELISA in 76 CAD patients and 82 CAD-free subjects. RESULTS: Serum sTWEAK concentrations were significantly lower in the patients (534.5+/-110.9 microg/L) than in the controls (688.1+/-150.0 microg/L, p<0.001), even after adjusting for different confounders (p<0.001). The areas under ROC curves (AUC)s calculated for logistic regression models that included different known risk factors were significantly increased when sTWEAK was added to the corresponding model (p=0.011-0.035). CONCLUSIONS: The measurement of serum sTWEAK concentrations improves the prediction of CAD based on existing biomarkers.
OBJECTIVES: Decreased concentrations of circulating soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) were recently reported to be associated with atherosclerosis, but there are still no data concerning its predictive performance. DESIGN AND METHODS: The current cross-sectional study investigates the potential of the novel atherosclerotic biomarker for the prediction of coronary artery disease (CAD). Serum sTWEAK was measured by ELISA in 76 CAD patients and 82 CAD-free subjects. RESULTS: Serum sTWEAK concentrations were significantly lower in the patients (534.5+/-110.9 microg/L) than in the controls (688.1+/-150.0 microg/L, p<0.001), even after adjusting for different confounders (p<0.001). The areas under ROC curves (AUC)s calculated for logistic regression models that included different known risk factors were significantly increased when sTWEAK was added to the corresponding model (p=0.011-0.035). CONCLUSIONS: The measurement of serum sTWEAK concentrations improves the prediction of CAD based on existing biomarkers.
Authors: Mahmut Ilker Yilmaz; Juan Jesús Carrero; Jose Luis Martín-Ventura; Alper Sonmez; Mutlu Saglam; Turgay Celik; Halil Yaman; Mujdat Yenicesu; Tayfun Eyileten; Juan Antonio Moreno; Jesús Egido; Luis Miguel Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2010-04-29 Impact factor: 8.237
Authors: Hengdao Liu; Dan Lin; Hong Xiang; Wei Chen; Shaoli Zhao; Hui Peng; Jie Yang; Pan Chen; Shuhua Chen; Hongwei Lu Journal: Exp Ther Med Date: 2017-06-14 Impact factor: 2.447
Authors: Jesús M Gómez-Martin; Enrique Aracil; María Insenser; Gema de la Peña; Miguel A Lasunción; Julio Galindo; Héctor F Escobar-Morreale; José A Balsa; José I Botella-Carretero Journal: Obes Facts Date: 2020-05-08 Impact factor: 3.942
Authors: Valvanera Fernández-Laso; Cristina Sastre; Jose M Valdivielso; Angels Betriu; Elvira Fernández; Jesús Egido; Jose L Martín-Ventura; Luis M Blanco-Colio Journal: Clin J Am Soc Nephrol Date: 2016-01-04 Impact factor: 8.237